Robert W. Baird Issues Positive Forecast for Danaher (NYSE:DHR) Stock Price

Posted by Stanley Muller on Oct 22nd, 2026

Danaher (NYSE:DHR – Get Free Report) had its price target upped by Robert W. Baird from $246.00 to $254.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has an “outperform” rating on the conglomerate’s stock. Robert W. Baird’s price target suggests a potential upside of 8.55% from the stock’s current price.

A number of other equities analysts have also weighed in on the company. UBS Group assumed coverage on Danaher in a research note on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price objective for the company. Barclays reissued an “overweight” rating and set a $260.00 target price on shares of Danaher in a research note on Thursday. Wells Fargo & Company lowered their price target on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 22nd. Guggenheim upped their price target on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Finally, Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Two analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $235.86.

Read Our Latest Stock Analysis on Danaher

Danaher Stock Up 4.3%

Shares of DHR stock opened at $233.99 on Thursday. The company has a market capitalization of $164.49 billion, a price-to-earnings ratio of 41.56, a PEG ratio of 2.82 and a beta of 0.76. Danaher has a one year low of $160.93 and a one year high of $242.80. The company’s fifty day moving average price is $215.25 and its 200-day moving average price is $196.84. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25.

Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.92 by $0.19. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.55 billion for the quarter, compared to analysts’ expectations of $6.56 billion. During the same quarter in the previous year, the company earned $1.89 EPS. Danaher’s revenue for the quarter was up 8.3% on a year-over-year basis. Sell-side analysts expect that Danaher will post 8.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in DHR. Prime Capital Investment Advisors LLC lifted its position in shares of Danaher by 0.5% in the third quarter. Prime Capital Investment Advisors LLC now owns 9,203 shares of the conglomerate’s stock worth $2,039,000 after buying an additional 45 shares in the last quarter. Veery Capital LLC boosted its stake in Danaher by 3.1% during the third quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after buying an additional 48 shares during the last quarter. Studio Investment Management LLC grew its holdings in Danaher by 3.3% during the 2nd quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock valued at $302,000 after buying an additional 51 shares in the last quarter. OLD Second National Bank of Aurora grew its holdings in Danaher by 0.5% during the 1st quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock valued at $2,297,000 after buying an additional 57 shares in the last quarter. Finally, Adelphi Trust Co grew its holdings in Danaher by 2.5% during the 3rd quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock valued at $524,000 after buying an additional 57 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

More Danaher News

Here are the key news stories impacting Danaher this week:

Positive Sentiment: Danaher reported adjusted earnings of $2.11 per share, above the $1.92 analyst consensus and up from $1.89 a year earlier. Revenue rose 8.3% to $6.55 billion, narrowly below or effectively in line with the $6.56 billion estimate. Danaher Reports Third Quarter 2026 Results
Positive Sentiment: The company raised its full-year 2026 adjusted EPS outlook to $8.57-$8.62, signaling confidence that improving customer demand and operating performance will continue. Danaher Beats Profit Estimates, Raises Outlook as Customer Demand Improves
Positive Sentiment: Biotechnology was a key growth driver: orders increased at a mid-teens rate, while stronger profitability in the segment helped produce the earnings beat. Management also cited improving trends across several end markets. Danaher: 3 Key Takeaways for Long-Term Investors
Positive Sentiment: Management highlighted artificial-intelligence capabilities as a potential long-term growth opportunity in drug discovery, describing Danaher as having the foundational technologies—or “building blocks”—to participate in the market. Danaher says it has building blocks for AI drug discovery growth
Neutral Sentiment: The acquisition of Masimo helped offset weaker respiratory diagnostic sales, suggesting integration benefits but also continued softness in parts of the diagnostics portfolio. Danaher’s Masimo acquisition offsets drops in respiratory diagnostic sales
Negative Sentiment: Revenue did not materially exceed expectations, and the ongoing CEO transition could create uncertainty around execution and Danaher’s strategic priorities despite the stronger outlook. Danaher drops after Q3 revenue miss amid CEO transition

About Danaher

(Get Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.